|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.93/0.75
|
企业价值
16.15M
|
资产负债 |
每股账面净值
-1.36
|
现金流量 |
现金流量率
--
|
损益表 |
收益
--
|
每股收益
--
|
同行比较
|
||||||||||||||||
|
报价延迟最少15分钟:2024/04/20 02:30 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medicalneed. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease. |